← Leaderboards
Marisa Wong Medina
Children'S Hospital & Res Ctr At Oakland
$12,012,626
Attributed
$13,123,495
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.8M · FY2010–24$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$24,315,405 · 7
By mechanism
P50$16,646,677 · 2
R01$5,936,574 · 3
R56$1,732,154 · 2
Top collaborators
- Ronald M Krauss6 shared
- Aldons Jake Lusis6 shared
- Aras Nikodemas Mattis4 shared
Others in their field
Top investigators on “Lipids”
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Alan M Fogelman · University Of California Los Angeles$57,458,120
- Paul M. Ridker · Brigham And Women'S Hospital$56,179,451
- Adrian Hernandez · Duke University$50,769,596
- Garret A Fitzgerald · University Of Pennsylvania$50,340,498
- Richard A Gibbs · Baylor College Of Medicine$49,140,324
Research focus
LipidsMolecularGeneticIn VivoIn VitroKnock-DownLeadCell ModelPhenotypeBaseVariantPathway InteractionsGenesCell LinePlasmaOverexpressionAnimal ModelMouse ModelCholesterolCardiovascular Disorder RiskGenetic VariantGenome-WideEnzymesHepatocyte
Grant awards (28)
TMEM55B as a molecular determinant of NAFLD$563,952
R56 · FY2024 · DK · contact PI
Genetic Regulation of Nonalcoholic Fatty Liver Disease$537,831
R01 · FY2024 · DK · contact PI
TMEM55B as a molecular determinant of NAFLD$591,003
R56 · FY2023 · DK · contact PI
Genetic Regulation of Nonalcoholic Fatty Liver Disease$560,240
R01 · FY2023 · DK · contact PI
Genetic Regulation of Nonalcoholic Fatty Liver Disease$564,108
R01 · FY2022 · DK · contact PI
Genetic Regulation of Nonalcoholic Fatty Liver Disease$559,560
R01 · FY2021 · DK · contact PI
The Role of Phosphatidylinositides in Lipid Metabolism$420,401
R01 · FY2021 · HL · contact PI
The Role of Phosphatidylinositides in Lipid Metabolism$375,266
R01 · FY2020 · HL · contact PI
The Role of Phosphatidylinositides in Lipid Metabolism$52,256
R01 · FY2020 · HL · contact PI
Pharmacogenomics of Statin Therapy$1,524,688
P50 · FY2019 · GM
Pharmacogenomics of Statin Therapy$1,173,979
P50 · FY2019 · GM
Molecular Determinants of Statin Efficacy and Adverse Effects in Cellular Models$818,437
P50 · FY2019 · GM · contact PI
The Role of Phosphatidylinositides in Lipid Metabolism$453,443
R01 · FY2019 · HL · contact PI
Pharmacogenomics of Statin Therapy$2,667,664
P50 · FY2018 · GM
Molecular Determinants of Statin Efficacy and Adverse Effects in Cellular Models$1,297,478
P50 · FY2018 · GM · contact PI
The Role of Phosphatidylinositides in Lipid Metabolism$446,268
R01 · FY2018 · HL · contact PI
Phamarcogenomics of Statin Therapy (SUPPLEMENT)$395,986
P50 · FY2018 · GM
Pharmacogenomics of Statin Therapy$2,688,571
P50 · FY2017 · GM
Molecular Determinants of Statin Efficacy and Adverse Effects in Cellular Models$1,146,873
P50 · FY2017 · GM · contact PI
Pharmacogenomics of Statin Therapy$2,741,022
P50 · FY2016 · GM
Molecular Determinants of Statin Efficacy and Adverse Effects in Cellular Models$1,057,429
P50 · FY2016 · GM · contact PI
Functional Dissection of the 19p13.11 Haplotype$577,199
R56 · FY2016 · HL · contact PI
Molecular Determinants of Statin Efficacy and Adverse Effects in Cellular Models$1,134,550
P50 · FY2015 · GM · contact PI
Alternative Splicing in Regulation of Cholesterol Synthesis and Uptake$389,293
R01 · FY2014 · HL · contact PI
Alternative Splicing in Regulation of Cholesterol Synthesis and Uptake$378,170
R01 · FY2013 · HL · contact PI
Alternative Splicing in Regulation of Cholesterol Synthesis and Uptake$397,238
R01 · FY2012 · HL · contact PI
Alternative Splicing in Regulation of Cholesterol Synthesis and Uptake$401,250
R01 · FY2011 · HL · contact PI
Alternative Splicing in Regulation of Cholesterol Synthesis and Uptake$401,250
R01 · FY2010 · HL · contact PI